GW Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of GW Pharmaceuticals generated cash of -$27,385,000, which is more than the previous year. Cash used in financing activities reached the amount of -$1,129,000 last year. Net change in cash is therefore -$50,181,000.
Cash Flow
| 2010 | 6.83M | -527.57K | 991.97K |
|---|---|---|---|
| 2011 | 3.66M | -1.00M | 2.17M |
| 2012 | 2.90M | -1.71M | 117.82K |
| 2013 | -12.07M | -3.35M | 29.50M |
| 2014 | -20.50M | -11.52M | 234.29M |
| 2015 | -70.42M | -26.96M | 194.60M |
| 2016 | -110.22M | -11.40M | 269.46M |
| 2017 | -147.69M | -20.44M | -2.75M |
| 2018 | -231.86M | -32.88M | 297.75M |
| 2020 | -27.38M | -28.00M | -1.12M |
GWPH Cash Flow Statement (2010 – 2020)
| 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 536.93M | 322.15M | 501.56M | 306.03M | 249.27M | 61.82M | 47.42M | 45.70M | 39.32M | 32.54M |
Operating activities | ||||||||||
Net income | -58.12M | -295.16M | -176.41M | -82.94M | -67.53M | -23.80M | -7.35M | 4.01M | 4.28M | 7.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 12.75M | 9.29M | 7.39M | 4.77M | 3.48M | 2.27M | 1.59M | 1.21M | 916.98K | 1.14M |
Stock-based compensation expense | 58.35M | 31.62M | 15.88M | 10.62M | 3.75M | 2.01M | 995.82K | 1.62M | 1.23M | 995.13K |
| Deferred income tax benefit | 58.35M | 31.62M | 15.88M | 10.62M | 3.75M | 2.01M | 995.82K | 1.62M | 1.23M | 995.13K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -22.10M | -804K | -3.65M | -981.15K | -1.53M | -230.61K | -174.59K | 982.92K | 0 | 0 |
Inventories | -39.87M | -13.64M | -128.60K | 568.10K | -18.18K | 474.22K | -960.26K | -1.31M | -1.00M | -361.72K |
Accounts payable | 9.86M | 2.23M | -4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -27.38M | -231.86M | -147.69M | -110.22M | -70.42M | -20.50M | -12.07M | 2.90M | 3.66M | 6.83M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -28.00M | -33.40M | -22.36M | -11.97M | -27.32M | -11.78M | -3.62M | -2.12M | -1.38M | -685.53K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -28.00M | -32.88M | -20.44M | -11.40M | -26.96M | -11.52M | -3.35M | -1.71M | -1.00M | -527.57K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 297.93M | 0 | 269.13M | 193.72M | 206.85M | 31.96M | 0 | 2.23M | 1.07M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -1.82M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -882K | -798K | 0 | -165.48K | 0 | -162.40K | -17.78K | -11.29K | 0 | 0 |
Cash used in financing activities | -1.12M | 297.75M | -2.75M | 269.46M | 194.60M | 234.29M | 29.50M | 117.82K | 2.17M | 991.97K |
Net Change In Cash | -50.18M | 32.75M | -178.46M | 181.79M | 106.65M | 205.31M | 14.11M | 1.63M | 4.83M | 7.29M |
Cash at end of period | 486.75M | 354.91M | 323.09M | 487.83M | 355.92M | 267.14M | 61.54M | 47.34M | 44.16M | 39.83M |
| Data source |